Literature DB >> 7511666

Complement-inhibiting activities of human CD59 and analogues from rat, sheep, and pig are not homologously restricted.

C W van den Berg1, B P Morgan.   

Abstract

Human erythrocyte CD59 and analogues isolated from erythrocytes of rat, sheep, and pig were examined for their ability to protect erythrocytes from various species against lysis by C from homologous and heterologous sources. In all cases, incorporation of human CD59 or analogues from rat, sheep, and pig efficiently protected guinea pig erythrocytes against lysis by C homologous with the CD59. However, each of the CD59 analogues also conferred on guinea pig erythrocytes protection against C from most heterologous species. These results demonstrate that none of the CD59 analogues tested were species specific in their C-inhibiting activity. Erythrocytes from species other than guinea pig could not be protected by incorporation of any of the available CD59 analogues despite similar incorporation in all erythrocytes tested. We suggest that the presence of endogenous inhibitors on these other erythrocytes masks the activity of incorporated CD59. Evidence that is supportive of this hypothesis was provided by demonstrating that blocking the endogenous CD59 with mAbs rendered erythrocytes susceptible to inhibition by high dosages of incorporated CD59.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7511666

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  17 in total

1.  Production and functional analysis of rat CD59 and chimeric CD59-Crry as active soluble proteins in Pichia pastoris.

Authors:  R J Quigg; C He; B K Hack; J J Alexander; B P Morgan
Journal:  Immunology       Date:  2000-01       Impact factor: 7.397

2.  Molecular cloning of the rat analogue of human CD59: structural comparison with human CD59 and identification of a putative active site.

Authors:  N K Rushmere; R A Harrison; C W van den Berg; B P Morgan
Journal:  Biochem J       Date:  1994-12-01       Impact factor: 3.857

3.  Binding of human and rat CD59 to the terminal complement complexes.

Authors:  T Lehto; B P Morgan; S Meri
Journal:  Immunology       Date:  1997-01       Impact factor: 7.397

4.  Expression of rat CD59: functional analysis confirms lack of species selectivity and reveals that glycosylation is not required for function.

Authors:  N K Rushmere; S Tomlinson; B P Morgan
Journal:  Immunology       Date:  1997-04       Impact factor: 7.397

5.  Xenotransplanted Pig Sertoli Cells Inhibit Both the Alternative and Classical Pathways of Complement-Mediated Cell Lysis While Pig Islets Are Killed.

Authors:  Kandis Wright; Rachel Dziuk; Payal Mital; Gurvinder Kaur; Jannette M Dufour
Journal:  Cell Transplant       Date:  2016-11       Impact factor: 4.064

6.  Absence of CD59 in Guinea Pigs: Analysis of the Cavia porcellus Genome Suggests the Evolution of a CD59 Pseudogene.

Authors:  Hani Boshra; Wioleta M Zelek; Timothy R Hughes; Santiago Rodriguez de Cordoba; B Paul Morgan
Journal:  J Immunol       Date:  2017-11-22       Impact factor: 5.422

7.  Mutational analysis of the active site and antibody epitopes of the complement-inhibitory glycoprotein, CD59.

Authors:  D L Bodian; S J Davis; B P Morgan; N K Rushmere
Journal:  J Exp Med       Date:  1997-02-03       Impact factor: 14.307

8.  Human and rodent decay-accelerating factors (CD55) are not species restricted in their complement-inhibiting activities.

Authors:  C L Harris; O B Spiller; B P Morgan
Journal:  Immunology       Date:  2000-08       Impact factor: 7.397

9.  Characterization in vitro and in vivo of the pig analogue of human CD59 using new monoclonal antibodies.

Authors:  S M Hanna; G T Williams; C W Van Den Berg; B P Morgan
Journal:  Immunology       Date:  1998-11       Impact factor: 7.397

10.  Analysis of human CD59 tissue expression directed by the CMV-IE-1 promoter in transgenic rats.

Authors:  B Charreau; L Tesson; J Buscail; J P Soulillou; I Anegon
Journal:  Transgenic Res       Date:  1996-11       Impact factor: 2.788

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.